| Sage Academy | |
|
3900 85th Ave N, Brooklyn Park, MN 55443-1908 | |
| (763) 315-4020 | |
| (763) 315-4028 |
| Full Name | Sage Academy |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 3900 85th Ave N, Brooklyn Park, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497024855 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sage Academy 3900 85th Ave N, Brooklyn Park, MN 55443-1908 Ph: (763) 315-4020 | Sage Academy 3900 85th Ave N, Brooklyn Park, MN 55443-1908 Ph: (763) 315-4020 |
News Archive
Generations of neuroscientists have been indoctrinated into believing that our senses, thoughts, feelings and movements are orchestrated by a communication network of brain cells, or neurons, each responsible for relaying one specific chemical message called a neurotransmitter.
There's a dark side to obesity that's only recently getting attention; millions of people from all walks of life are often stigmatized and even shamed based on their weight -and it's one of the most pervasive and acceptable forms of bias and discrimination. In advance of Weight Stigma Awareness Week (September 21-25), Stacey Cahn, PhD, associate professor of clinical psychology at Philadelphia College of Osteopathic Medicine, discusses the causes and consequences of weight stigma.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.
› Verified 8 days ago
Mr. Steven J. Chargo, MA, CCC, AUDIOLOGIST Audiologist Medicare: Accepting Medicare Assignments Practice Location: 10000 Zane Ave N, Brooklyn Park, MN 55443 Phone: 763-744-1190 Fax: 763-744-0547 |